Access cutting-edge hereditary transthyretin-mediated amyloidosis with polyneuropathy treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Rochester location
Preparing your pre-screening questions…
Access hereditary transthyretin-mediated amyloidosis with polyneuropathy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hereditary transthyretin-mediated amyloidosis with polyneuropathy treatment provided free
Check if you qualify for this hereditary transthyretin-mediated amyloidosis with polyneuropathy clinical trial in Rochester, MN
No-Cost Study Care
Local to Rochester
Convenient for MN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Sponsor: Alnylam Pharmaceuticals
Yes, this clinical trial (NCT07223203) has an active research site in Rochester, MN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for hereditary transthyretin-mediated amyloidosis with polyneuropathy treatment options in Rochester, MN, this clinical trial (NCT07223203) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hereditary transthyretin-mediated amyloidosis with polyneuropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all hereditary transthyretin-mediated amyloidosis with polyneuropathy clinical trials near you to find additional studies recruiting in your area.
See all neuropathy clinical trials recruiting in Rochester — not just this study.
Browse Neuropathy Trials in Rochester →